Abstract: Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions.

Abstract: Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions.

Abstract: The present invention describes a method for the treatment of periodontal disease. The method may include applying a characterized acellular Mesenchymal Stem Cell (MSC) derived composition from a screened donor to a periodontal tissue. The method may also include delivering a scaffold to the periodontal tissue wherein the scaffold topically delivers the characterized acellular MSC derived composition.

Abstract: The present disclosure provides inventive cosmetic/dermatological formulations and/or preparations that include mesenchymal stem cells (MSCs), and also provides associated methods for repairing, rejuvenating and/or augmenting skin tissue. The formulations and/or preparations include MSCs that are formulated into creams, lotions, and the like. In one aspect, the MSCs are obtained autogenously. In another aspect, the MSCs are obtained from allogeneic sources. In another aspect, the MSCs may be minimally manipulated. In another aspect, the MSCs may be derived from bone marrow or adipose tissue. In another aspect, the MSCs can be utilized from bone marrow concentrate (BMC) or from adipose stromal vascular fraction (SVF). In another aspect, the MSCs can also be utilized after cell expansion. The associated methods comprise topical application of the cosmetic/dermatological formulations and/or preparations onto skin tissue, resulting in repairing, rejuvenating, and/or augmenting the skin tissue.

Abstract: The present disclosure provides an inventive method of treating deteriorated skin tissue in the face or selected areas of the body, wherein the skin tissue has deteriorated due to aging and/or other factors, by injecting mesenchymal stem cells (MSCs) into these areas, resulting in improving and/or restoring the affected areas. In one aspect, the MSCs are obtained autogenously. In another aspect, the MSCs are minimally manipulated. In yet another aspect, treatment of the skin tissue is carried out using bone marrow concentrate that contains the MSCs. A platelet rich plasma (PRP) may be added to a bone marrow concentrate containing MSCs.

Abstract: The present disclosure provides an inventive method of treating inflammation that is associated with osteoarthritis of the knee joint by injecting mesenchymal stem cells into the symptomatic knee. In one aspect, the mesenchymal stem cells are obtained autogenously. In another aspect, the mesenchymal stem cells are injected below the degenerated medial tibial plateau of the knee joint, resulting in reduction of the inflammation and alleviation of the symptoms of the osteoarthritis.

Abstract: The present disclosure provides an inventive method of treating inflammation that is associated with osteoarthritis of the knee joint by injecting mesenchymal stem cells into the symptomatic knee. In one aspect, the mesenchymal stem cells are obtained autogenously. In another aspect, the mesenchymal stem cells are injected below the degenerated medial tibial plateau of the knee joint, resulting in reduction of the inflammation and alleviation of the symptoms of the osteoarthritis.

Abstract: The present novel technology relates to an autologous cell therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further relates to a method of using the composition to reduce discogenic pain in humans.

Abstract: The present novel technology relates to an autologous cell therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further relates to a method of using the composition to reduce discogenic pain in humans.